Pancreatic cancer has long been recognized as one of the most formidable challenges in oncology. With a disheartening five-year survival rate hovering around 10%, this aggressive malignancy remains a leading cause of cancer-related deaths worldwide. Recent advancements in treatment, particularly immunotherapy, have sparked hope, yet many patients inevitably face resistance to these therapies. However, groundbreaking…
Read more
Revolutionizing Pancreatic Cancer Treatment: The Promise of SH-273 in Overcoming Immunotherapy Resistance



